Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults
Status: Enrolling
Updated:  8/5/2015
San Juan City Hosp. PR NICHD CRS (5031)
mi
from
San Juan,
IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults
Status: Enrolling
Updated: 8/5/2015
San Juan City Hosp. PR NICHD CRS (5031)
mi
from
San Juan,
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1241.21.0004 Boehringer Ingelheim Investigational Site
mi
from
San Francisco, CA
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1241.21.0004 Boehringer Ingelheim Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1245.25.10068 Boehringer Ingelheim Investigational Site
mi
from
Washington,
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1245.25.10068 Boehringer Ingelheim Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1220.19.0004 Boehringer Ingelheim Investigational Site
mi
from
Vero Beach, FL
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1220.19.0004 Boehringer Ingelheim Investigational Site
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1220.19.0079 Boehringer Ingelheim Investigational Site
mi
from
Lutherville, MD
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1220.19.0079 Boehringer Ingelheim Investigational Site
mi
from
Lutherville, MD
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1220.48.0027 Boehringer Ingelheim Investigational Site
mi
from
Framingham, MA
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1220.48.0027 Boehringer Ingelheim Investigational Site
mi
from
Framingham, MA
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1218.75.004 Boehringer Ingelheim Investigational Site
mi
from
Camden, NJ
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1218.75.004 Boehringer Ingelheim Investigational Site
mi
from
Camden, NJ
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1220.19.0009 Boehringer Ingelheim Investigational Site
mi
from
Hillsborough, NJ
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1220.19.0009 Boehringer Ingelheim Investigational Site
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1218.74.01229 Boehringer Ingelheim Investigational Site
mi
from
Albany, NY
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1218.74.01229 Boehringer Ingelheim Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1199.15.10020 Boehringer Ingelheim Investigational Site
mi
from
Winston-Salem, NC
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1199.15.10020 Boehringer Ingelheim Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Austin, TX
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
205.452.01111 Boehringer Ingelheim Investigational Site
mi
from
Palm Springs, CA
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
205.452.01111 Boehringer Ingelheim Investigational Site
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated:  8/6/2015
1220.19.5502 Boehringer Ingelheim Investigational Site
mi
from
Rio de Janeiro - RJ,
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.
Status: Enrolling
Updated: 8/6/2015
1220.19.5502 Boehringer Ingelheim Investigational Site
mi
from
Rio de Janeiro - RJ,
Click here to add this to my saved trials
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1
Status: Enrolling
Updated:  8/10/2015
Fenway Community Health
mi
from
Boston, MA
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1
Status: Enrolling
Updated: 8/10/2015
Fenway Community Health
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Alabama Therapeutics CRS
mi
from
Birmingham, AL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Alabama Therapeutics CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Usc La Nichd Crs
mi
from
Alhambra, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Usc La Nichd Crs
mi
from
Alhambra, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
University of California, UC San Diego CRS
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
University of Southern California CRS
mi
from
Los Angeles, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
University of Southern California CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
UCLA CARE Center CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Stanford AIDS Clinical Trials Unit CRS
mi
from
Palo Alto, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Stanford AIDS Clinical Trials Unit CRS
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
UCSD Antiviral Research Center CRS
mi
from
San Diego, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
UCSD Antiviral Research Center CRS
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Ucsf Hiv/Aids Crs
mi
from
San Francisco, CA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Ucsf Hiv/Aids Crs
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
University of Colorado Hospital CRS
mi
from
Aurora, CO
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
University of Colorado Hospital CRS
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Denver Public Health CRS
mi
from
Denver, CO
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Denver Public Health CRS
mi
from
Denver, CO
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Georgetown University CRS (GU CRS)
mi
from
Washington,
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Georgetown University CRS (GU CRS)
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Howard Univ. Washington DC NICHD CRS
mi
from
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
South Florida CDTC Ft Lauderdale NICHD CRS
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Pediatric Perinatal HIV Clinical Trials Unit CRS
mi
from
Miami, FL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Pediatric Perinatal HIV Clinical Trials Unit CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
mi
from
Miami, FL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
The Ponce de Leon Ctr. CRS
mi
from
Atlanta, GA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
The Ponce de Leon Ctr. CRS
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Northwestern University CRS
mi
from
Chicago, IL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Northwestern University CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Rush Univ. Med. Ctr. ACTG CRS
mi
from
Chicago, IL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Rush Univ. Med. Ctr. ACTG CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Rush University CRS
mi
from
Chicago, IL
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Rush University CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Tulane Univ. New Orleans NICHD CRS
mi
from
New Orleans, LA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Tulane Univ. New Orleans NICHD CRS
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
IHV Baltimore Treatment CRS
mi
from
Baltimore, MD
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
IHV Baltimore Treatment CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Johns Hopkins University CRS
mi
from
Baltimore, MD
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Johns Hopkins University CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Massachusetts General Hospital CRS (MGH CRS)
mi
from
Boston, MA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Massachusetts General Hospital CRS (MGH CRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated:  8/11/2015
Bmc Actg Crs
mi
from
Boston, MA
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
Status: Enrolling
Updated: 8/11/2015
Bmc Actg Crs
mi
from
Boston, MA
Click here to add this to my saved trials